While Mr. Oostra declined to name the genetics firm to The Blade, he said he plans to meet with the firm’s executive leadership during his five-day trip to learn more about the Chinese healthcare system and explore additional hospital consulting and management opportunities.
ProMedica has made several investments in personalized medicine initiatives. For example, the health system is testing tumors for genetic signals to select the right chemotherapy treatments for patients.
“Having a better understanding of genetics is increasingly important to most appropriately treat diseases,” Mr. Oostra said, adding that the firm ProMedica is wooing would also boost the health system’s research and clinical care, as well as help improve Toledo’s economy.
ProMedica already maintains several clinical relationships with Chinese hospitals, including a 1,000-bed children’s and women’s facility, Mr. Oostra said. An outreach facility in China could also give Chinese medical residents and research fellows opportunities to practice medicine at ProMedica in the U.S.
To access the full report, click here.
More articles on leadership:
Partners HealthCare opens center of excellence for preventive care, chronic care
Healthcare is top draw for voters, Texas Medical Center poll finds
$4K inflatable colon stolen in Missouri
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.